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Abstract
CRISPR/Cas9 technology is currently considered the most advanced tool for targeted
genome engineering. Its sequence-dependent specificity has been explored for locus-
directed transcriptional modulation. Such modulation, in particular transcriptional activation,
has been proposed as key approach to overcome silencing of dormant HIV provirus in
latently infected cellular reservoirs. Currently available agents for provirus activation, so-
called latency reversing agents (LRAs), act indirectly through cellular pathways to induce
viral transcription. However, their clinical performance remains suboptimal, possibly
because reservoirs have diverse cellular identities and/or proviral DNA is intractable to the
induced pathways. We have explored two CRISPR/Cas9-derived activator systems as tar-
geted approaches to induce dormant HIV-1 proviral DNA. These systems recruit multiple
transcriptional activation domains to the HIV 5’ long terminal repeat (LTR), for which we
have identified an optimal target region within the LTR U3 sequence. Using this target
region, we demonstrate transcriptional activation of proviral genomes via the synergistic
activation mediator complex in various in culturemodel systems for HIV latency. Observed
levels of induction are comparable or indeed higher than treatment with established LRAs.
Importantly, activation is complete, leading to production of infective viral particles. Our data
demonstrate that CRISPR/Cas9-derived technologies can be applied to counteract HIV
latency and may therefore represent promising novel approaches in the quest for HIV
elimination.
Introduction
HIV latency constitutes the chief barrier to curative therapy in HIV-infected subjects [1]. It
designates a state of viral dormancy established in resting CD4+ T cells and other long-lived
immune cell populations upon hours after viral infection. Dormancy is characterized by
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transcriptional silencing of the integrated proviral genome through various mechanisms
[2–4]. Although a rare occurrence with an estimated frequency of 1 to 60 cells per million
CD4+ T cells, latently-infected HIV reservoirs persist for years in infected individuals,
evading immune surveillance or antiretroviral therapy [5,6]. While thought to be largely
harmless in their latent state, reservoir cells retain the capacity to spontaneously activate the
provirus and therefore persistently spread virus. Current strategies for HIV cure focus pri-
marily on eradicating latent reservoirs through inducing proviruses to form viral particles,
and subsequent clearing of infected cells by cytopathic viral or immune surveillance mecha-
nisms [1,7].
Several classes of latency reversing agents (LRAs) for pharmacological induction of proviral
transcription have been tested in ex vivo latency models or clinical trials. These include protein
kinase C agonists (e.g. phorbol esters, Prostratin, Bryostatin); histone deacetylase inhibitors
(HDACis, e.g. Vorinostat/SAHA, Romidepsin), and bromodomain and extraterminal bromo-
domain inhibitors (BETis, e.g. JQ-1) [8–12]. These agents have been found to activate tran-
scription by inducing T cell activation through signaling pathways, modulating epigenetic
states, or regulating transcriptional elongation [13]. However clinical performance of current
LRAs remains suboptimal. So far no trials have shown significant reduction in latent reservoirs
upon LRA treatment combined with antiretroviral therapy [1,14]. Inefficient clearance of acti-
vated reservoir cells might partly explain these findings. However, several lines of evidence also
indicate that transcriptional activation of latent HIV genomes by currently available LRAs is
insufficient. First, a subset of latent proviruses in CD4+ T cells of HIV infected individuals was
found to be intractable to ex vivo stimulation by LRAs [6]. Second, for latent cells of non-CD4
+ identity, such as myeloid-derived microglial cells or macrophages, the activity of some LRAs
has been reported as poor [9]. In line with these observations, HIV latency was described to be
predominantly viral-encoded and cellular targets of current LRAs might play a secondary role
in transcriptional regulation [15].
Approaches that promote transcriptional activation of proviral DNA independently of the
cellular state could circumvent these drawbacks. One possible strategy is to directly target tran-
scriptional activators to HIV proviral LTR sequences. Indeed, both zinc finger protein-derived
modulators and transcriptional activator-like effector (TALE) proteins designed to be specific
for HIV LTR mediate activation in latency models [16–18]. Directed transcriptional activation
can also be achieved using CRISPR/Cas9-derived technologies (CRISPR: clustered regularly
interspaced palindromic repeats; Cas9: CRISPR-associated protein 9) [19–24]. As RNA-depen-
dent DNA-binding effectors, these technologies have the substantial advantage that targeting
specificity is programmable simply through choosing appropriate guide RNA (gRNA)
sequences.
Here, we investigated whether CRISPR/Cas9-derived activation systems can be applied to
reverse HIV latency. We explored two systems: the SunTag and synergistic activation media-
tor (SAM) systems [25,26]. Both technologies rely on recruiting multiple transcriptional acti-
vation domains to a DNA target using sequence-complementary gRNA and enzymatically
inactive Streptococcus pyogenes (Sp) Cas9 nuclease-derived proteins. We identified an opti-
mal target region in the U3 sequence of the HIV 5’LTR, and demonstrate that recruitment of
SAM in particular induced robust transcriptional activation of HIV genomes in various in
vitro latency models. Importantly, levels of activation were comparable or indeed superior to
those observed after exposure to established LRAs. Reversal of latency was apparently com-
plete, with induction not only at the RNA and protein level, but also generating infectious
particles. Our data present proof of concept that CRIPSR/Cas9-derived activation systems
meet all the prerequisites for novel tools to complement current strategies for HIV latency
reversal.
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Results
Identifying an optimal target region for CRISPR/Cas9-derived activation
systems in the HIV 5’LTR
We explored two CRISPR/Cas9-derived activator systems for HIV transcriptional induction
(Fig 1A). In the SunTag system synthetic transcriptional activator VP64 (derived from four
copies of the herpes virus transcriptional activation domain VP16) is fused to single chain vari-
able fragment (scFv) antibodies with binding specificity for peptides derived from the general
control protein 4 (GCN4) [26]. Co-expression of these antibodies together with dCas9 (Cas9
nuclease-derived enzymatically inactive protein) fused to GCN4-containing peptide tags (Sun-
Tag) and gRNAs, leads to spatial recruitment of multiple VP64 domains to the gRNA-comple-
mentary target sites. The SAM (synergistic activation mediator) system [25] comprises three
components: dCas9-VP64 fusion protein, modified gRNA (mod. gRNA) containing aptamers
bound by MS2 bacteriophage coat protein, and MS2 proteins fused to NF-κB trans-activating
subunit p65 and heat-shock factor 1 (HSF1) activation domain. Co-expression of these compo-
nents establishes a multi activation domain-containing SAM complex mediating transcrip-
tional activation at the gRNA-determined target site.
To identify an optimal target region for functionally recruiting SunTag and SAM systems to
HIV proviral DNA, we first designed several gRNAs (gRNA1-9) specific for HIV 5’LTR. We
focused in particular on a region within the U3 sequence (gRNA3-8), that is known to harbor a
number of transcription factor binding sites and has recently been successfully exploited for
TALE-mediated activation (Fig 1B) [16]. NGG SpCas9 protospacer adjacent motif (PAM) sites
determined the gRNA sequence choice. Components of the SunTag (Fig 1C) and SAM (Fig
1D) systems together with single gRNAs were transiently expressed in HeLa cell-derived clonal
TZM-bl cells carrying an HIV LTR-dependent luciferase reporter [27]. SunTag and SAM
components expressed without any gRNA served as negative controls. For both systems we
observed strong activation of reporter gene expression when targeting with gRNA3-6. While
SunTag-mediated activation was generally lower, with a maximum of three-fold activation
over controls (gRNA4), SAM-mediated activation reached levels of up to 11-fold over controls
(gRNA5 and gRNA6; Fig 1C and 1D). Notably, induction of luciferase transcription was highly
specific to the recruiting gRNA, with gRNA7-9 failing to induce reporter gene expression
above background levels.
These results indicate an optimal target region spanning gRNA3-6 located 230 bp to 106 bp
upstream of the transcriptional start site (TSS) for directed transcriptional activation of HIV
5’LTR using the SunTag and SAM systems. In particular the SAM system showed strong effects
on reporter gene transcription in TZM-bl cells. Notably, these effects are potentiated by co-
expression of two gRNAs within the optimal target region, leading to synergistic activation
conceivably through recruitment of multiple SAM complexes (Fig 1D). Moreover, activation
achieved through SAM system recruitment was also superior to reporter induction by dCas9-
VP64 alone (S1 Fig).
SAM-mediated reversal of HIV latency in T cell-derived model systems
Next we investigated whether CRISPR/Cas9-derived activation systems could be used to
reverse transcriptional latency of HIV genomes, a key aspect in current purging approaches to
eliminate HIV reservoirs. We focused on the SAM system using gRNA5 for optimal targeting,
based on its superior activating effects seen in TZM-bl cells. We explored two T cell-derived
latency models, the widely used JLat model [28] and a newly established dual-color HIV
reporter model system [29].
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Jurkat-derived clonal JLat6.3 cells carry a replication-incompetent HIV-derived GFP
reporter (Fig 2A), which is silenced in untreated cells, resembling a state of viral latency. To
test SAM-mediated activation potential, JLat6.3 clones were transiently co-transfected with
components of the SAM system plus optimal target gRNA5, gRNA8 (complementary to a neg-
ative target sequence, see Fig 1), or no gRNA (control). GFP reporter gene expression levels
were measured by flow cytometry at 48, 72 and 96 h post transfection. Importantly, expression
of SAM components in control cells did not result in significant activation of reporter tran-
scription, indicating a robust silenced state that remains unperturbed by transient transfection.
Fig 1. Identifying an optimal target region for SunTag and synergistic activation mediator (SAM) systems in the
HIV 5‘LTR. (A) Scheme of SunTag and SAM activation systems. In both systems binding of a guide RNA (gRNA) to a
specific target DNA sequence results in recruitment of multiple activator domains (VP64, HSF1, p65; see text for details).
(B) HIV 5’LTR (HXB2) sequence with complimentary gRNAs1-9. (C, D) The effect of SunTag (C) and SAM (D) systems
on LTR activation was tested by transient expression of gRNAs and system components in TZM-bl cells carrying a
luciferase reporter under HIV LTR control. Activation levels were measured 48 h post transfection using a luciferase
assay on whole cell lysates. Activation is shown as fold increase (light units/transfected cell) over the negative control (no
gRNA expression). Shown are results of three (C; D, left panel) and two (D, right panel) independent experiments.
doi:10.1371/journal.pone.0158294.g001
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However the HIV reporter in JLat6.3 cells was strongly activated upon expression of the SAM
complex targeted through the optimal gRNA5. Induced cells reached levels of 42% as early as
48 h post transfection and further increased to around 69% GFP-positive cells at 96 h (Fig 2B).
Moreover, induction was highly dependent on the gRNA5 sequence, with no significant activa-
tion seen with gRNA8 (Fig 2B).
We then compared SAM-mediated reporter induction levels to those achieved by treating
JLat6.3 cells with established LRAs used at clinically relevant concentrations as previously
reported [30]. The HDAC inhibitor Vorinostat and protein kinase C agonist Prostratin only
minimally induced the GFP reporter after 24 h of exposure (Fig 2C). Treatment with HDAC
inhibitor Romidepsin or phorbol 12-myristate 13-acetate (PMA) and Ionomycin, a combina-
tion used for maximal ex vivo stimulation of HIV expression in viral outgrowth assays, led to
induction levels of around 17% and 25% in the JLat model, respectively (Fig 2C). Exposure to
higher LRA concentrations only moderately increased induction rates and often resulted in
reduced cell viability (S2 Fig).
Taken together these results demonstrate strong SAM-mediated activation of latent HIV-
reporter in JLat6.3 cells, with induction levels superior to those achieved using established
LRAs.
Different in vitromodels of HIV latency have shown variable responses to LRAs [31]. To
test whether SAM-mediated latency reversal also demonstrates variable effects, we used a sec-
ond, newly established latency system. This system, called HIVis (HIV visible), comprises an
HIV-1 reporter variant [29,32] with a dual fluorescent marker cassette inserted into the nef
locus within an HIV-1-derived replication-incompetent vector backbone. The marker cassette
encodes blue fluorescent protein (BFP) under HIV LTR control and Venus-fluorescent protein
Fig 2. SAM-mediated latency reversal in the JLat model. (A) Scheme of the replication-incompetent HIV
reporter virus present in Jlat6.3 cells. Transcriptional activation results in LTR-dependent eGFP expression.
(B) Components of the SAM system together with gRNA5, gRNA8 or no gRNA (control) were transiently
expressed in JLat6.3 cells and proviral activation was measured by flow cytometry at 48, 72, and 96 h post
transfection. Two-way ANOVA was used for statistical evaluation (in relation to control); *** signifies
p<0.001. (C) Proviral activation levels in JLat6.3 cells after 24 h exposure to different latency reversing
agents as measured by flow cytometry. Shown are results of three independent experiments (B, C).
doi:10.1371/journal.pone.0158294.g002
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under the control of constitutive spleen focus-forming virus (SFFV) promoter (Fig 3A, left).
Upon transduction with HIVis reporter, flow cytometry analysis can readily distinguish
between non-transduced cells and transduced cell populations with different states of HIVis
reporter transcriptional activity, thereby enabling visualization of productive versus latent
infection (Fig 3A, right panel). Notably, latent HIVis reporter is responsive to LRA exposure,
which induces viral gene expression at RNA and protein level (S3 Fig).
We generated a clonal Jurkat cell-derived HIVis cell line (HIVisB2), carrying a single HIVis
reporter integrated at the nup188 locus in a latent state. LTR-dependent transcription, as mea-
sured by BFP expression, is minimal or absent in HIVisB2 cells (<3% of the total cell popula-
tion), but can be induced by exposure to LRAs (S1 Fig). This HIVisB2 model was then used to
test SAM-dependent LTR activation (Fig 3B). As observed with JLat6.3 clones, transient
expression of SAM together with optimal gRNA5 induced strong expression of the latent HIV
reporter: levels of activated cells were 21% after 48 h, reaching 51% at 96 hours. Again, this
induction was highly specific for recruitment to the optimal target region, with no LTR tran-
scription seen in control cells or cells co-expressing gRNA8 (Fig 3B). In comparison, treating
HIVisB2 cells with clinically relevant LRAs led to induction levels of 4% (Vorinostat), 27%
(Prostratin) and 57% (Romidepsin). Stronger induction could be achieved by using increased
LRA concentrations, this however lead to marked reduction in viability for the HDAC inhibi-
tors (S2 Fig). Stimulation with the most potent ex vivo agents PMA and Ionomycin led to
robust activation levels of around 73% (Fig 3C).
Importantly, we confirmed that expression of the bfpmarker in SAM-activated HIVisB2
cells correlated with up-regulation of cell-associated tat and gag RNA (Fig 3D). Furthermore,
these cells also expressed cell-associated p24 protein, indicating that SAM-mediated activation
via gRNA5 recruitment reversed HIV silencing in HIVisB2 cells (Fig 3E).
Taken together, these data demonstrate that SAM effectively activates transcription of latent
HIV genomes at high levels across different in vitromodel systems.
Exposure to SAM converts latent state into productive viral life cycle
Several currently applied LRAs may only promote incomplete induction of latent provirus, fail-
ing to stimulate production of fully replication-competent viral progeny [8]. To test whether
robust SAM-mediated activation of HIV LTR-driven transcription can also induce production
and release of infectious viral particles in formerly latent cells, we employed the J89 model sys-
tem [33]. As opposed to JLat6.3 and HIVis systems, Jurkat-derived clonal J89 cells carry a fully
replication-competent HIV-derived provirus with an eGFP marker (Fig 4A). This reporter pro-
virus is latent under non-induced culture conditions (<2% GFP positive cells) [33]. Consistent
with our results described above, transient expression of SAM and gRNA5 resulted in strong
induction of J89 cells, with 66% GFP positive cells after 48 h and up to 89% induced cells at 96
hours (Fig 4B). Induction was also accompanied by up-regulation of cell-associated p24 levels
in formerly latent J89 cells (Fig 4C).
To test for viral particle production, we used a transwell culture system to co-culture SAM-
activated, GFP-expressing J89 cells (72 h post transfection with SAM/gRNA5) with MOLT-4/
CCR5 cells. As previously described, this transformed CD4+ T cell line served as a host to
amplify any J89-derived infectious particles (Fig 4D) [8]. Co-culture of non-transfected J89
cells with MOLT-4/CCR5 cells served as control (untreated). After seven days of co-culture,
gag RNA levels were measured by digital droplet PCR (ddPCR) in both co-culture supernatant
and MOLT-4/CCR5 host cells. We detected significant levels of gag RNA in co-culture super-
natant after seven days, indicating viral particle release from SAM-activated J89 cells (Fig 4E,
S4 Fig). Consistent with this finding, we observed significant levels of cell-associated gag RNA
HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Activators
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Fig 3. Latency reversal using SAM in the HIVis model system. (A) Scheme of replication incompetent HIVis
latency reporter virus (left panel). Transcriptional activation results in LTR-dependent BFP expression, while the
SFFV promoter drives constitutive expression of Venus fluorescent protein. Upon transduction of Jurkat cells
with HIVis reporter, cells with active LTR transcription (II: BFP+, Venus+) can be distinguished from cell
populations with a silenced LTR (III: BFP-, Venus+) or non-transduced cells (I: BFP-, Venus-) by flow cytometry
(right panel). (B) Components of the SAM system together with gRNA5, gRNA8 or no gRNA (control) were
transiently expressed in clonal HIVis cells (HIVisB2). Proviral activation was monitored by flow cytometry at 48,
72, and 96 h post transfection. Two-way ANOVA was used for statistical evaluation (in relation to control);
** signifies p<0.01. (C) Proviral activation levels in HIVisB2 cells after 24 h exposure to different latency
reversing agents. (D) Levels of cell-associated tat and gag RNA in HIVisB2 cells as measured by qRT-PCR at
72 h post transfection with SAM system components plus gRNA5, gRNA8 or no gRNA (control). One-way
ANOVAwas used for statistical evaluation; * signifies p<0.05. Shown are results of three (B, C) and two (D)
independent experiments. (E) Number of HIVisB2 cells showing BFP expression (upper panel) and cell-
associated p24 expression (lower panel) at 72 h post transfection with SAM system components and gRNA5,
gRNA8 or no gRNA (control). Insert shows a flow cytometry contour plot of p24 and BFP co-expression in
control (grey) and SAM/gRNA5 transfected (red) cells.
doi:10.1371/journal.pone.0158294.g003
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Fig 4. Induction of HIV replication using SAM in the J89 latencymodel. (A) Scheme of replication-
competent HIV reporter virus in J89 clones. Transcriptional activation results in LTR-dependent eGFP
expression and viral replication. (B) Components of the SAM system together with gRNA5, gRNA8 or no
gRNA (control) were transiently expressed in J89 cells and proviral activation was determined by flow
cytometry at 48, 72, and 96 h post transfection. Two-way ANOVA was used for statistical evaluation (in
relation to control); *** signifies p<0.001. Shown are results of three independent experiments. (C) Number
of J89 cells showing eGFP expression (upper panel) and cell-associated p24 expression (lower panel) at 72
h post transfection with SAM system components and gRNA5, gRNA8 or no gRNA (control). Inset shows flow
cytometry contour plot of p24 and eGFP co-expression in control (grey) and SAM/gRNA5 transfected (red)
cells. (D) To assess viral replication after SAM-mediated activation, J89 cells transfected with SAM
components and gRNA5, were sorted for eGFP expression and co-cultured at 72 h post transfection with
MOLT-4/CCR5 cells using a transwell system. (E) At 7 days post initiation of the co-culture, levels of gag
RNA in co-culture supernatants and MOLT-4/CCR5 cells (cell-associated) were measured using ddPCR. Co-
culture of non-transfected J89 cells with MOLT-4/CCR5 cells served as control (untreated). Mann-Whitney U
test was used for statistical evaluation (in relation to untreated); * signifies p<0.05. (F) At 12 days post
initiation of the co-culture, cell-associated LTR DNA content was determined in MOLT-4/CCR5 cells. Levels
HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Activators
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in MOLT-4/CCR5 cells exposed to activated J89 (Fig 4E, S4 Fig). These results indicate that
MOLT-4/CCR5 cells were infected by J89-derived viral particles induced through SAM-medi-
ated activation. In support, we also detected levels of HIV-LTR-derived DNA in MOLT-4/
CCR5 cells after twelve days of co-culture with activated J89 cells (Fig 4F, S4 Fig). Taken
together, these data indicate that targeted activation using the SAM system can transform
latent HIV provirus into actively replicating states.
Functional effects of sequence variations in optimal target gRNA on
SAM-mediated LTR activation
Having demonstrated that SAM components together with gRNA5 can specifically activate
latent HIV genomes, our results prompt the possibility of using this activation system on latent
reservoirs in vivo. Since LTR sequences in HIV isolates often diverge among and between viral
subtypes, we therefore went on to ask how variations in optimal gRNA sequences affect SAM-
mediated provirus activation.
We first determined to what extent gRNA3, -4, -5 and -6 sequences are conserved within
the optimal LTR target region based on the Los Alamos National Laboratory HIV sequence
database (Fig 5A; www.hiv.lanl.gov). Among all HIV-1 subtypes, as well as subtype B or C
alone, the gRNA5 sequence is the most conserved, present in 5% of all deposited sequences,
and in 13% of subtype B or 0.5% of subtype C isolates. Allowing for point mutations within the
20 nt gRNAs, tolerating two mutations increases sequence conservation of gRNA5 to 26% for
all subtypes, 34% for subtype B and 31% for subtype C. For all retrieved HIV sequences, our
database searches revealed that gRNA3, -4 and -6 are much less conserved than gRNA5, with
at least nine mutations required for a sequence match of 50% or more, as opposed to four
mutations for gRNA5 (Fig 5A).
Focusing on gRNA5, we further examined the nucleotide positions that vary most fre-
quently in this gRNA target sequence: variation primarily occurs at nucleotides two and four in
the 5’ region, position 10 in the central region, and positions 14 and 16 in the seed region of the
gRNA (Fig 5B). To test how mutations at these various positions affect SAM-mediated activa-
tion, we generated mutants of gRNA5. In these mutants nucleotides were substituted according
to frequently occurring variations at the specific site (e.g. gRNA5 2 indicates gRNA5 2A>G;
see S5 Fig). We then co-expressed these gRNA5 mutants and SAM components in TZM-bl
cells and assayed for luciferase reporter activity. Mutations at positions 2 or 10 in gRNA5 had
little effect on SAM-mediated LTR activation (gRNA5 2, gRNA5 10; Fig 5C). Mismatches at
both positions reduced activation by about 50% (i.e. gRNA5 2,10). However, mutations within
the seed region (e.g. gRNA5 16) virtually abolished SAM-mediated LTR induction. This
observation is in agreement with previously published data showing that sequence mismatches
immediately upstream of the PAM site abolish binding of gRNAs to their respective targets
[34].
Discussion
Here, we present a proof of concept that CRISPR/Cas9-derived activation systems can be used
to induce latent HIV genomes. In particular, using the SAM system we achieved strong and
reproducible activation of latent proviruses, which importantly continued to the level of pro-
ducing infectious particles. We identified an optimal target region for recruiting CRISPR/Cas9
are shown as fold increase of LTR sequences per cell over untreated control. Shown are results of two
independent experiments (E, F).
doi:10.1371/journal.pone.0158294.g004
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activation systems to the HIV 5’LTR and demonstrate how sequence variations within this
region affect system activity.
Our findings are supported by recent studies that show in vitro reversal of HIV latency
using various engineered transcriptional activation systems based on CRISPR/Cas9 technology
[35–38]. These studies focused on different effector modules, such as fusions of dCas9 to
VP64 (dCas9-VP64), to VP64, p65 and Epstein-Barr virus R transactivator (Rta; dCas9-VPR),
to histone acetyltransferase p300 (dCas9-p300) as well as the SAM and SunTag systems.
Independently of the effector, all studies agree with our findings that CRISPR/Cas9-derived
Fig 5. Conservation of optimal gRNAs and the effect of sequence variation on SAM-mediated LTR activation. (A) Sequence conservation of
HXB2-derived gRNA3, -4, -5 and -6 based on the Los Alamos HIV Sequence Database considering all HIV subtypes (upper panel), subtype B only
(middle panel) or subtype C only (lower panel). Percentages of sequence hits are shown, allowing for 0 to 9 point mutations in the indicated gRNA
(see Materials and Methods for details). (B) Frequency distribution of gRNA5mutations observed in database hits according to nucleotide (nt)
position. Different colors indicate the number of mutations (1–9). (C) The effect of sequence variations in gRNA5 on SAM-mediated LTR activation
was tested by transient expression of gRNAmutants (gRNA *X, where X is the mutated nucleotide position) with SAM system components in TZM-
bl cells. Activation levels were measured at 48 h post transfection by luciferase assays performed on whole cell lysates. Activation is shown as fold
increase (light units/transfected cell) over negative control (no gRNA expression). Shown are results of two independent experiments.
doi:10.1371/journal.pone.0158294.g005
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technologies can induce transcription from latent HIV LTR in all culture models tested so far.
Furthermore, there is evident overlap in the target region identified for optimal recruitment of
activator complexes to HIV 5’LTR. Our data and published reports strongly indicate that
gRNAs complementary to sequence 164bp to 92bp upstream of the transcriptional start site
lead to optimal targeting (S6 Fig). Certain differences exist concerning the sequence of the
most efficient gRNA within this region, however these may be explained by variations in the
reporter systems used to test gRNA effectiveness and by differences in activator modules. A
comprehensive comparison between different CRISPR/Cas9-derived activator modules and
single as well as multiplexed targeting gRNAs should in future further clarify this issue.
Notably, in the context of recent reports on CRISPR/Cas9-based activators for HIV latency
reversal, our study focuses in particular on how viral gene expression correlates with LTR-tar-
geted activation. Here we are the first to demonstrate that induction using CRISPR/Cas9-der-
ived systems is complete, i.e. results in release of infectious particles, and thus transforms
dormant proviruses into replicative viral states in a T-cell derived model. This key finding qual-
ifies CRISPR/Cas9-based technologies for translational applications.
CRISPR/Cas9-derived approaches have a number of potentially significant advantages over
currently used LRAs. They can be used for LTR-targeted induction of latent HIV genomes,
reaching often much higher levels than reported for LRAs (see above; [35–38]). Their potential
for site-specific activation determined by gRNA sequence choice contrasts with currently
applied LRAs. These modulate global gene expression via cellular pathways, and harbor there-
fore considerable potential for undesired or toxic effects [39]. Notably, we provide evidence
that targeting of CRISPR/Cas9-derived systems can result in activation up to the release of
infectious particles. Such full activation is thought to be an essential prerequisite for purging
latent reservoir cells through immune surveillance as part of current eradication strategies [1].
It is also required for ex vivo identification and effective quantification of the reservoir—an
aspect of increasing interest and concern in view of tailoring suppressive therapy regimens.
Furthermore, as CRISPR/Cas9-derived activators circumvent activation of cellular pathways,
they hence likely reverse latency independently of cellular identities and activity states [37].
Since current findings point towards an increasingly heterogeneous reservoir, such activators
therefore have tremendous potential to revert latency across the full spectrum of dormant
HIV-infected cells [3]. Clearly, this may also hold true for TALE-based HIV activating strate-
gies [16,18]. However, in direct comparison, the ease with which CRISPR/Cas9-derived sys-
tems can be adapted to new target sequences may confer a considerable advantage.
In the future, current findings will need to be expanded to primary and patient-derived
HIV-infected cells. These studies will allow to address potential toxicity of CRISPR/Cas9-based
activator systems and mechanistic details of transcriptional induction, such as for example pro-
tein levels bound to DNA and epigenetic changes at the LTR promoter. In this context, it will
be critical to develop effective and safe vectors for delivery into primary cells. While the size of
activator modules currently prevents packaging into clinically preferred adeno-associated virus
(AAV) vectors [40], rapid technical advances in the field of CRISPR/Cas9-technologies will
likely soon circumvent this drawback. Sequential lentiviral delivery of activator complexes into
clonal cell lines has already been employed [35,38]. However, such applications are far from
reaching clinical translation. Here, we opted for transient transfection of activator complexes
to provide a proof of principle.
Our analysis of sequence conservation among targeting gRNAs within the HIV 5’LTR
touches on a second aspect relevant for translating CRISPR/Cas9-derived activators to clinical
applications. Our data indicate that 5’mutations in gRNAs are likely to be tolerated, while vari-
ations within the seed region abolish directed targeting, as previously reported [34]. Since
latent reservoirs harbor a variety of viral mutants, successful activation through CRISPR/
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Cas9-derived technologies will need to take into account sequence variations [41]. To bypass
any escape, delivery of multiple guide RNAs tailored towards these variations could be a suc-
cessful approach. Indeed, our findings indicate that expressing multiple gRNAs does not inter-
fere, but rather can potentiate CRISPR/Cas9-mediated activation.
In conclusion, much effort has been directed towards finding specific and potent LRAs to
eliminate HIV latent reservoirs. Here, we demonstrate that activation systems based on
CRISPR/Cas9-technology could be potent tools for this purpose. These tools are waiting to be
exploited to complement future latency reversing strategies ex vivo or potentially in the patient.
Materials and Methods
Plasmid construction
Expression plasmids for components of the SunTag and SAM system were obtained from
Addgene: pHRdSV40-dCas9-10xGCN4_v4-P2A-BFP (Addgene #60903, SunTag), pHRdSV40-
scFv-GCN4-sfGFP-VP64-GB1-NLS (Addgene #60904, SunTag), dCas9-VP64_GFP (Addgene
#61422, SAM), MS2-P65-HSF1_GFP (Addgene #61423, SAM). For expression of SAM compo-
nents in JLat6.3 and J89 cells, the T2A-GFP sequence was replaced by the T2A-BFP sequence at
theNhe1/EcoR1 restriction sites (MS2-P65-HSF1_BFP). The gRNA sequences were derived
from HXB2 (TZM-bl, JLat6.3, J89 cells) and NL4-3 (HIVisB2 cells) viral genomes. For expres-
sion, gRNA sequences were cloned as oligonucleotides (Sigma) into pSUPER (Oligoengine; Sun-
Tag system; H1 promoter-dependent expression) or sgRNA(MS2) cloning backbones (Addgene
#61424; SAM system; U6 promoter-dependent expression). To compare effects of complete ver-
sus incomplete SAM system expression (see S1 Fig), the following expression constructs were
used: MS2-P65-HSF1_BFP, lenti_sgRNA (MS2)_SFFV_Venus (based on Addgene #61427 with
insertion of SFFV_Venus sequences at the BamH1/EcoR1 restriction sites) and dCas9-VP64_m-
Cherry (based on Addgene #61422 with replacement of the T2A-GFP sequence by the T2A-
mCherry sequence at theNhe1/EcoR1 restriction sites). The proviral construct pNLT2-HIVis
was generated by replacing the BlpI-XhoI fragment of construct pNLT2ΔenvPuro [42] with the
coding sequence for BFP followed by the SFFV promoter and coding sequence for Venus-fluo-
rescent protein (Fig 3A).
Cell culture
The following reagents were obtained through the NIH AIDS Reagent Program, Division of
AIDS, NIAID, NIH: TZM-bl from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc.
[27]; J-Lat Full Length Clone 6.3 from Dr. Eric Verdin [28]; MOLT-4/CCR5 from Dr. Masa-
nori Baba, Dr. Hiroshi Miyake, and Dr. Yuji Iizawa. J89 cells were a kind gift from Dr. David
N. Levy (New York University) [33]. HEK293 (ATCC catalogue #CRL-1573) and TZM-bl cells
were cultured in Dulbecco’s modified Eagle medium (DMEM, Biochrom) supplemented with
10% fetal calf serum (Biochrom), 4 mM L-glutamine (Biomol), 50 U/ml penicillin and strepto-
mycin (PenStrep, Biochrom) at 37°C and 5% CO2. Jurkat (ATCC catalogue #TIB-152), JLat6.3,
HIVisB2 and J89 cells were maintained in RPMI 1640 (Lonza) supplemented with 10% FCS
(PAN, Biotech), 4 mM L-glutamine, 50 U/ml penicillin and streptomycin (PenStrep; Bio-
chrom) at 37°C and 5% CO2. Media for MOLT-4/CCR5 was additionally supplemented with 1
mg/ml G418 (Gibco Life Technologies).
HIVis infection and generation of HIVisB2 cell line
Pseudotyped HIVis lentiviral particles were produced as previously described [43]. In short,
HEK293 cells were transiently transfected with proviral pNLT2-HIVis plasmid and pCMV-
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VSV-G [44] using transfection reagent TransIT-LT1 (Mirus Bio) according to the manufactur-
er’s protocol. Viral supernatants were collected 72 h post transfection. To generate Jurkat-
HIVis cells, Jurkat cells were infected with pseudotyped pNLT2-HIVis (MOI 0.1) in the pres-
ence of 5 μg/ml protamine sulfate (Sigma-Aldrich) and spinoculated at 300 x g for 10 min at
ambient temperature. After spinoculation cells were cultivated at 37°C and 5% CO2 for 5 h and
subsequently medium was changed. Jurkat-HIVis cells were sorted for Venus-positive cells on
a fluorescent activated cell sorting (FACS) Aria system (BD Biosciences) 4 weeks after infec-
tion. Single cell clones were generated via repeated limiting dilution in 96-well plates to identify
the HIVisB2 clone. Proviral integration site was determined by HiLo-PCR as described before
[43].
Transient transfection assays, firefly-luciferase reporter assay and
treatment with LRAs
For transient expression of SunTag or SAM system components, TZM-bl cells were seeded at 2
x 105 cells/ml and JLat6.3, HIVisB2, or J89 cells at 5 x 105 cells/ml in 6-well plates 24 h prior to
transfection. Transient transfection of TZM-bl cells was performed with Lipofectamine 2000
(Thermo Fisher Scientific) according to the manufacturer’s protocol. JLat6.3, HIVisB2 and J89
cells were transfected using TransIT-Jurkat (Mirus Bio) according to the manufacturer’s proto-
col. Cells were co-transfected in triplicate with the following amounts of plasmid/6-well: 1)
SunTag system: 0.9 μg pH1-gRNA1-9, 1.2 μg pHRdSV40-dCas9-10xGCN4_v4-P2A-BFP and
1.9 μg pHRdSV40-scFv-GCN4-sfGFP-VP64-GB1-NLS; 2) SAM system: 0.9 μg sgRNA(MS2)-
gRNA1-9, 1.3 μg dCas9-VP64_GFP and 1.8 μg MS2-P65-HSF1_GFP. For luciferase reporter
assays, whole cell lysates were prepared 48 h post transfection and treated using Luciferase
Reporter Assay System (Promega) according to the manufacturer’s protocol. Measurements
were performed using a Centro LB 960 luminometer (Berthold Technologies) and Mikro-
Win2000 software (Mikrotek). For treatment with LRAs, cells were seeded at 1 x 106 cells/ml
and treated with the following concentrations of agents unless otherwise stated: 40 nM Romi-
depsin (MedChem Express), 335 nM Vorinostat (Sigma Aldrich), 300 nM Prostratin (Sigma
Aldrich), 50 ng/ml phorbol 12-myristate 13-acetate (PMA; Sigma Aldrich) or 1 μM Ionomycin
(Sigma-Aldrich).
AlamarBlue cell viability assay
For cell viability assessment, 100 μl of treated cell cultures were plated in triplicate in 96-well
plates and 20 μl AlamarBlue reagent (AbD Serotec) was added. Plates were incubated at 37°C
and 5% CO2 for 2 h and absorbance was measured at 570/600 nm using a VERSAmax micro-
plate reader (Molecular Devices). Viable cells reduce the active ingredient of AlamarBlue
reagent (resazurin) to resorufin, which absorbs at 570/600 nm.
Transwell co-culture assay
J89 cells were transfected with SAM system components and enriched for GFP-positive cells 72
h post transfection using a FACS Aria Fusion (BD Biosciences). Sorted J89 and MOLT-4/
CCR5 recipient cells were co-cultured in 24-well Transwells (PET membrane, 0.4 μm pore size,
Corning Costar) at a ratio of 1:20 (J89 upper well, MOLT-4/CCR5 lower well). At 7 days post
co-culture, supernatant was taken from the transwell system for RNA isolation. At the same
time point, 50% of MOLT-4/CCR5 cells were taken from the co-culture for isolation of cell-
associated RNA. At 12 days post co-culture, the remaining MOLT-4/CCR5 cells were isolated
from the co-culture for genomic DNA isolation.
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Flow cytometry, p24 staining and immunoblot analysis
Transfected cells were washed twice in PBS and analyzed using a Canto II flow cytometer (BD
Biosciences). J89 cells were fixed in 2% paraformaldehyde (Sigma Aldrich) prior to analysis.
Data was analyzed using FlowJo vX.0.7 software (Tree Star). To account for transfection effi-
ciency, JLat6.3 and J89 cells were gated on BFP expression and HIVisB2 cells were gated on
GFP expression. For intracellular p24 staining, HIVisB2 cells were enriched for GFP-express-
ing transfected cells using a FACS Aria system (BD Biosciences). Transfected J89 and HIVisB2
cells were washed twice with PBS and fixed with 4% paraformaldehyde for 20 min in the dark.
Cells were then washed with Perm/Wash buffer (BD Biosciences) and incubated with 250 μl
Cytofix/Cytoperm solution (BD Biosciences) for 30 min at 4°C in the dark. Cells were washed
again and stained with 2 μl of anti-HIV-1 core antigen clone KC57-RD1 (Beckman Coulter) in
50 μl of Perm/Wash buffer for 60 min at 4°C in the dark. Cells were washed and subsequently
analyzed using a Canto II flow cytometer (BD Biosciences). For immunoblot analysis, cell pel-
lets were lysed in E1A lysis buffer (150 mMNaCl, 50 mMHEPES, pH 7.0, 0.1% Nonidet P-40,
5 μg/ml leupeptin, 5 μg/ml aprotinin, 5 μg/ml pepstatin A, 125 μg/ml pefabloc (all protease
inhibitors from Biomol)) on ice for 30 min. Protein samples were resolved by electrophoresis
on a 15% SDS polyacrylamide gel and blotted onto nitrocellulose membrane. HIV-1 Gag and
β-Tubulin were detected with anti-Gag (clone CHE-CAP, diluted 1:10,000, Davids Biotechno-
logie) and anti-α-Tubulin (clone B-5-1-2, diluted 1:5,000, Sigma-Aldrich) and visualized with
IRDye-coupled secondary antibodies (diluted 1:10,000, LI-COR Biosciences) on a LI-COR
Odyssey Imaging System (LI-COR Biosciences).
qRT-PCR and ddPCR analysis
For qRT-PCR, total cellular RNA was isolated using peqGOLD TriFast (peqlab) according to
the manufacturer’s protocol. DNase treatment was performed using RQ1 DNase (Promega)
and DNase-treated RNA samples were reverse transcribed with M-MLV reverse transcriptase
(Promega) using an oligo-dT primer mix. Quantitative real-time PCR (qRT-PCR) was carried
out using Platinum Quantitative PCR SuperMix-UDG (Life Technologies) on a 7500 Fast
Real-Time PCR System (Applied Biosystems). The following primers were used for qRT-PCR:
tat-F (GGCATCTCCTATGGCAGGAA), tat-R (TGCTTTGATAGAGAAACTTGATGAGTCT),
tat-probe (5'(FAM)-ACAGCGACGAAGAGCTCATCAGAACAGT-(TAMRA)3'),
gag-F (ATCAATGAGGAAGCTGCAGAA), gag-R (GATAGGTGGATTATGTGTCAT), gag-probe
(5'-(FAM)-ATTGCACCAGGCCAGATGAGAGAA-(TAMRA)-3'),
gapdh-F (GTCATCAATGGAAATCCCATCA), gapdh-R (TGGTTCACACCCATGACGAA),
gapdh-probe (5'-(FAM)-TCTTCCAGGAGCGAGATCCCTC-(TAMRA)-3').
The amplification profile involved initial denaturation at 95°C for 3 min and 40 cycles of
denaturation at 95°C for 15 sec and hybridization and elongation at 60°C for 30 sec. All sam-
ples were assayed in quadruplicate wells. For ddPCR analysis, RNA from supernatant and total
cellular RNA was isolated using RNAzol (Sigma-Aldrich) according to the manufacturer’s pro-
tocol. Genomic DNA was isolated using QIAamp DNA micro Kit (Quiagen). Nucleic acid
quantities were determined by NanoDrop (Thermo Fisher Scientific). ddPCR for HIV gag
RNA was carried out using the QX200 platform from BioRad. cDNA samples were prepared as
described above. For the quantification of HIV gag RNA, primers and probe as indicated for
qRT-PCR were used (quencher BHQ1 instead of TAMRA). For cellular HIV gag RNA expres-
sion analysis, gapdh expression was determined as a control using the PrimePCR ddPCR
Expression Probe Assay: GAPDH (Human, HEX; BioRad). All samples were assayed in dupli-
cate wells. The mastermix/well included the following: 2 x ddPCR Supermix for Probes
(noUTP) (BioRad) 1:2, gag-F (1 μM), gag-R (1 μM), gag-probe (250 nM), template cDNA
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0.5 μl, filled up to 20 μl total volume with RNase free water. When measured target concentra-
tions were very low, template input was increased to 5 μl and runs were repeated. For gapdh
expression analysis, separate duplicate wells/sample were prepared, the template cDNA was
diluted 1:10, and 1 μl of the GAPDH Expression Probe Assay was added to the 20 μl reaction
(900 nM primers, 250 nM probe). “No-template” controls (NTC) containing water instead of
cDNA were included in duplicates for all assays. Subsequently, this mastermix was used for oil
droplet generation using a QX200 Droplet Generator, according to the manufacturer’s instruc-
tions. The droplets were transferred to 96-well twin.tec PCR Plates (Eppendorf), the plates
were heat-sealed with tin foil and placed in a thermal cycler with a 105°C heated lid (Analytik
Jena). Thermal cycling was carried out using the following parameters: 1 x (95°C 10 min), 40 x
(94°C 30 sec– 55°C 1 min), 1 x (98°C 10 min), 4°C (hold), with a 2°C/sec ramping rate. After
thermal cycling, plates were immediately placed into the QX200 ddPCR Plate Reader, and
droplets were analyzed using QuantaSoft software, version 1.7.4. Following the run, amplitude
and cluster data were exported, and fluorescence thresholds for positive-negative event dis-
crimination and target concentrations in the ddPCR runs were determined using the function
‘ddPCRquant’ in R Studio (version 0.99, RStudio Inc.) [45]. For cell-associated HIV DNA anal-
ysis, primers and a 6-FAM-labeled fluorescent probe binding in a highly conserved region of
the LTR in the HIV genome were used (‘Generic HIV DNA Cell’, Biocentric) [46]. To quantify
HIV genomes/cell, the concentration of the single copy gene rpp30 was determined in parallel
(PrimePCR ddPCR Copy Number Assay RPP30, HEX, BioRad). The mastermix/well included
the following: 2 x ddPCR Supermix for Probes (noUTP) 10 μl, HIV-LTR forward and reverse
primers as well as the HIV-LTR probe (400 nM each), RPP30 Copy Number Assay (900 nM
primers/250 nM probe) and 5 μl template DNA, filled up to 20 μl total volume with RNase free
water. Droplet generation and reading, as well as data analysis was carried out as described for
RNA measurements, the thermal cycling protocol was as follows: 1 x (95°C 10 min), 40 x (94°C
30 sec– 56.2°C 1 min), 1 x (98°C 10 min), 4°C (hold), with a 2°C/sec ramping rate.
Bioinformatics analysis
Bioinformatics analysis was based on the Los Alamos National Laboratory HIV sequence data-
base (www.hiv.lanl.gov). All HIV-1-sequences within the database were filtered for sequences
containing the genomic region from base position 241 to 348 (HXB2 annotation), resulting in a
set of 3033 sequences. Using this set, all sequences with a specific Hamming distance to gRNA3,
-4, -5 or -6 were counted, and the exact positions of the matching errors were estimated.
To count sequences, for Hamming distance dH and gRNA-sequence sgRNA with length lgRNA,
every sequence sdb of the HIV-database with length ldb was split into k-mers of length k = lgRNA,
resulting in n = ldb − lgRNA + 1 k-mers. If one k-mer with Hamming distance dH between k-mer
and sgRNA existed, the sequence count was increased by 1. For each of the n k-mers with Ham-
ming distance dH between k-mer and sgRNA the exact positions of the matching errors were
determined. Finally, a multiple sequence alignment (MSA) over all k-mers of the HIV-database
with Hamming distance dH between the k-mer and sgRNA was generated with Clustal Omega
[47]. Afterwards the MSA was used to generate a sequence logo using Weblogo 2.8.2 [48].
Statistical analysis
Statistical analysis was performed using Prism version 5.03 software (Graph Pad). The statisti-
cal significance was assessed by one-way or two-way analysis of variance (ANOVA) followed
by a Bonferroni’s Multiple Comparison Test or Mann-Whitney U test. A result of p<0.05 was
considered to be statistically significant.
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Supporting Information
S1 Fig. Comparison of SAM-mediated activation to single dCas9-VP64- or MS2p65HSF1-
mediated effects. The effect of gRNA5-targeted SAM system (dCas9-VP64 + MS2p65HSF1
+ gRNA5) on LTR activation was compared to gRNA5-targeted expression of Cas9-VP64 or
MS2p65HSF1 alone in transient transfection assays in TZM-bl cells carrying a luciferase
reporter under HIV LTR control. Activation levels were measured 48 h post transfection using
a luciferase assay on whole cell lysates. Activation is shown as fold increase (light units/trans-
fected cell) over the negative control (no gRNA expression). Shown are results of two indepen-
dent experiments.
(PDF)
S2 Fig. Treatment of JLat6.3 and HIVisB2 with different concentrations of latency revers-
ing agents. JLat6.3 and HIVisB2 cells were exposed to different concentrations of latency
reversing agents (LRAs). Arrows indicate clinically relevant LRA concentrations as reported
previously [30](see also Figs 2C and 3C). Proviral activation levels in (A) JLat6.3 and (B)
HIVisB2 cells were measured by flow cytometry and cell viability was determined by Alamar-
Blue cell viability assay. Values for AlamarBlue viability assay were normalized to those of
untreated cells. Shown are results of two independent experiments.
(PDF)
S3 Fig. Characterization of HIVis latency reporter in Jurkat cells and clonal HIVisB2 cells.
(A) Jurkat cells were transduced with VSV-G pseudotyped HIVis reporter, enriched for BFP
negative/Venus positive cells by FACS and exposed to 670 nM Ionomycin and 80 nM PMA for
6 h or left untreated. Cell-associated tat RNA levels in Venus expressing Jurkat-HIVis cells
were measured by qRT-PCR over a period of 7 days after stimulation and normalized to gapdh
RNA levels. (B) Levels of HIV Gag and cellular Tubulin were measured via immunoblots (6 μg
protein per sample). (C) Clonal HIVisB2 cells show LTR-dependent BFP expression after stim-
ulation with 10 nM PMA and 1 μM Ionomycin for 24 hours.
(PDF)
S4 Fig. Analysis of raw ddPCR data by ‘ddPCRquant’ in R Studio. After baseline alignment,
fluorescent threshold values for each run were calculated based on data from no-template con-
trol (NTC) wells using extreme value theory. Representative dot plots (NTC and baseline,
MOLT-4/CCR5 + untreated control J89 co-culture, MOLT-4/CCR5 + SAM/gRNA5 trans-
fected J89 co-culture) are shown for (A) co-culture supernatant gag cDNA, (B) co-cultured
MOLT-4/CCR5 cell-associated gag cDNA and (C) MOLT-4/CCR5 cell-associated HIV-1 LTR
DNA assays. See Materials and Methods for details on the experimental setup.
(PDF)
S5 Fig. Sequence logos showing residue conservation of HXB2-derived gRNA5. The Los
Alamos HIV Sequence Database (all HIV subtypes) was used for conservation studies.
Sequences are shown for 0 to 9 allowed point mutations.
(PDF)
S6 Fig. Optimal gRNAs for recruitment of CRISPR/Cas9-derived activator systems to the
HIV 5’ LTR. Scheme of HIV 5’LTR showing localization of gRNAs (arrows) that have been
reported as most effective for recruitment of different CRISPR/Cas9-derived activator systems
in various independent studies (see table). Red arrows indicate localization of gRNAs3-6,
which were found in present study to define an optimal target region based on SAM-mediated
induction of TZM-bl reporter cells.
(PDF)
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